291 related articles for article (PubMed ID: 16642045)
1. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.
Martelli AM; Nyåkern M; Tabellini G; Bortul R; Tazzari PL; Evangelisti C; Cocco L
Leukemia; 2006 Jun; 20(6):911-28. PubMed ID: 16642045
[TBL] [Abstract][Full Text] [Related]
2. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
Doepfner KT; Spertini O; Arcaro A
Leukemia; 2007 Sep; 21(9):1921-30. PubMed ID: 17581609
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
4. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
5. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
[TBL] [Abstract][Full Text] [Related]
6. PI3K-Akt pathway: its functions and alterations in human cancer.
Osaki M; Oshimura M; Ito H
Apoptosis; 2004 Nov; 9(6):667-76. PubMed ID: 15505410
[TBL] [Abstract][Full Text] [Related]
7. Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.
Carlson CB; Robers MB; Vogel KW; Machleidt T
J Biomol Screen; 2009 Feb; 14(2):121-32. PubMed ID: 19196698
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers.
Michl P; Downward J
Z Gastroenterol; 2005 Oct; 43(10):1133-9. PubMed ID: 16220453
[TBL] [Abstract][Full Text] [Related]
9. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways.
Choi JA; Park MT; Kang CM; Um HD; Bae S; Lee KH; Kim TH; Kim JH; Cho CK; Lee YS; Chung HY; Lee SJ
Oncogene; 2004 Jan; 23(1):9-20. PubMed ID: 14712206
[TBL] [Abstract][Full Text] [Related]
10. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
11. The role of the PI3K-AKT pathway in melanoma.
Davies MA
Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
[TBL] [Abstract][Full Text] [Related]
13. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
14. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
15. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
17. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia].
Dos Santos C; Récher C; Demur C; Payrastre B
Bull Cancer; 2006 May; 93(5):445-7. PubMed ID: 16777621
[TBL] [Abstract][Full Text] [Related]
18. BacMam-enabled LanthaScreen cellular assays for PI3K/Akt pathway compound profiling in disease-relevant cell backgrounds.
Carlson CB; Mashock MJ; Bi K
J Biomol Screen; 2010 Mar; 15(3):327-34. PubMed ID: 20145103
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
20. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
